Results 11 to 20 of about 326,995 (379)

Adoptive immunotherapy against ovarian cancer [PDF]

Journal of Ovarian Research, 2016
The standard front-line therapy for epithelial ovarian cancer (EOC) is combination of debulking surgery and platinum-based chemotherapy. Nevertheless, the majority of patients experience disease recurrence. Although extensive efforts to find new therapeutic options, cancer cells invariably develop drug resistance and disease progression.
MITTICA, Gloria, Capellero, Sonia, GENTA, SOFIA, Cagnazzo, Celeste, AGLIETTA, Massimo, SANGIOLO, Dario, VALABREGA, Giorgio   +6 more
openaire   +4 more sources

Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response

OncoImmunology, 2017
Adoptive T cell therapy has emerged as a powerful strategy to treat human cancers especially haematological malignancies. Extension of these therapies to solid cancers remains a significant challenge especially in the context of defining immunological ...
Corey Smith, Victor Lee, Andrea Schuessler, Leone Beagley, Sweera Rehan, Janice Tsang, Vivian Li, Randal Tiu, David Smith, Michelle A. Neller, Katherine K. Matthews, Emma Gostick, David A. Price, Jacqueline Burrows, Glen M. Boyle, Daniel Chua, Benedict Panizza, Sandro V. Porceddu, John Nicholls, Dora Kwong, Rajiv Khanna   +20 more
doaj   +2 more sources

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Journal of Immunology Research, 2017
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells.
Baixin Ye, Creed M. Stary, Qingping Gao, Qiongyu Wang, Zhi Zeng, Zhihong Jian, Lijuan Gu, Xiaoxing Xiong   +7 more
doaj   +2 more sources

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Molecular Cancer, 2023
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration
Qiaofei Liu, Jia-Yao Li, Huaijin Zheng, Sen Yang, Yuze Hua, Nan Huang, J. Kleeff, Q. Liao, Wenming Wu   +8 more
semanticscholar   +1 more source

Natural killer cells in antitumour adoptive cell immunotherapy

Nature Reviews. Cancer, 2022
Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with intrinsic abilities to identify and eliminate virally infected cells and tumour cells.
Tamara J Laskowski, Alexander Biederstädt, K. Rezvani   +2 more
semanticscholar   +1 more source

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer

Nature Communications, 2021
Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and ...
Maik Luu, Zeno Riester, Adrian Baldrich, Nicole Reichardt, S. Yuille, A. Busetti, M. Klein, Anne Wempe, Hanna Leister, H. Raifer, F. Picard, K. Muhammad, K. Ohl, Rossana Romero, Florence Fischer, C. Bauer, M. Huber, T. Gress, M. Lauth, Sophia Danhof, T. Bopp, T. Nerreter, I. Mulder, U. Steinhoff, M. Hudecek, A. Visekruna   +25 more
semanticscholar   +1 more source

CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy

Nature Communications, 2021
The immunosuppressive tumor microenvironment (TME) represents a major barrier for effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous and plastic cell components of the TME which can either promote tumor progression (M2 ...
A. Rodríguez-García, Rachel C. Lynn, M. Poussin, Monika A. Eiva, Lauren Shaw, Roddy S. O’Connor, Nicholas G. Minutolo, Victoria Casado-Medrano, Gonzalo Lopez, T. Matsuyama, D. Powell   +10 more
semanticscholar   +1 more source

Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy

Nature Biomedical Engineering, 2021
Malignant transformation and tumour progression are associated with cancer-cell softening. Yet how the biomechanics of cancer cells affects T-cell-mediated cytotoxicity and thus the outcomes of adoptive T-cell immunotherapies is unknown.
Kewen Lei, Armand Kurum, Murat Kaynak, Lucia Bonati, Y. Han, Veronika Cencen, Min Gao, Yu-Qing Xie, Yugang Guo, M. Hannebelle, Yangping Wu, Guanyu Zhou, Ming Guo, G. Fantner, M. Sakar, Li Tang   +15 more
semanticscholar   +1 more source

Tracking adoptive T cell immunotherapy using magnetic particle imaging

Nanotheranostics, 2021
Adoptive cellular therapy (ACT) is a potent strategy to boost the immune response against cancer. ACT is effective against blood cancers but faces challenges in treating solid tumors.
Angelie Rivera-Rodriguez, L. Hoang-Minh, Andreina Chiu-Lam, Nicole S Sarna, Leyda Marrero-Morales, D. Mitchell, Carlos M. Rinaldi‐Ramos   +6 more
semanticscholar   +1 more source

A novel and effective cancer immunotherapy mouse model using antigen-specific B cells selected in vitro. [PDF]

PLoS ONE, 2014
Immunotherapies such as adoptive transfer of T cells or natural killer cells, or monoclonal antibody (MoAb) treatment have recently been recognized as effective means to treat cancer patients.
Tatsuya Moutai, Hideyuki Yamana, Takuya Nojima, Daisuke Kitamura   +3 more
doaj   +1 more source